Skip to main content
. 2019 Aug 19;8(8):1251. doi: 10.3390/jcm8081251

Figure 4.

Figure 4

Kaplan–Meier curves for radiographic progression-free survival (rPFS), time to PSA progression (TTPP), and overall survival (OS) from the initiation of the second-line treatment. Note that rPFS and TTPP from the initiation of the second line significantly favored enzalutamide following abiraterone compared to vice versa.